In This Section

Program: Monday, February 24

Sunday, Feb. 23 Tuesday, Feb. 25 Wednesday, Feb. 26

monday, february 24

*-Short talk from proffered abstract

Monday, February 24

continental breakfast 

7-8 a.m. | Platinum Ballroom F-J

Major Symposium 1: Personalized Therapies Targeting Neoantigens 

8-9:30 a.m. | Diamond Ballroom 4-5

Session Chair: Alena Gros, VHIO Vall D’Hebron Institute of Oncology, Barcelona, Spain

  • 8:05 a.m. | Personalized cancer vaccines: Encouraging results and new opportunities
    Catherine Wu, Dana-Farber Cancer Institute, Brookline, Massachusetts
  • 8:25 a.m. | Immunogenicity and therapeutic targeting of recurrently mutated ‘public’ neoantigens
    Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, New York, New York
  • 8:45 a.m. | Towards personalized minimally-invasive T-cell therapies
    Alena Gros
  • 9:05 a.m. | Discussion / Q&A

break

9:30-10 a.m. | Diamond Foyer

Major Symposia 2-3 

10-11:30 a.m.

Major Symposium 2: Cancer Immune Evasion 

Diamond Ballroom 4-5

Session Chair: Helen Rizos, Macquarie University, Sydney, Australia

  • 10:05 a.m. | Immune evasion – from CD8 to CD4 T cells
    Annette Paschen, University Hospital Essen, Essen, Germany
  • 10:25 a.m. | Hide and Seek: Immune evasion in melanoma
    Helen Rizos
  • 10:45 a.m. | A feed-forward loop in the adenosine signaling pathway drives myeloid-mediated resistance to immune checkpoint inhibition in prostate cancer*
    Aram Lyu, Fred Hutchinson Cancer Center, Seattle, Washington
  • 10:55 a.m. | Cancer cell intrinsic SSBP4 enables tumor immune evasion by promoting cholesterol biosynthesis*
    Peiqi Ou, Amgen, Inc., South San Francisco, California
  • 11:05 a.m. | Discussion / Q&A

Major Symposium 3: New Cancer Immunotherapy Biology 

Diamond Ballroom 1-3

Session Chair: Caroline Robert, Gustave Roussy, Paris, France

  • 10:05 a.m.| New developments in drugging the adenosine pathway
    Juan C. Jaen, Arcus Biosciences, Burlingame, California
  • 10:25 a.m. | Remote control CAR T cell therapy: Enhancing cellular functionality
    Christine E. Brown, City of Hope National Medical Center, Duarte, California
  • 10:45 a.m. | New development in translational control of T cells
    Caroline Robert
  • 11:05 a.m. | Discussion / Q&A

BREAK

11:30 a.m.-12 p.m. | Diamond Foyer

keynote session 2

12-1 p.m. | Diamond Ballroom 4-5

Session Chair: Ira Mellman, University of California, San Francisco, California

  • 12:05 p.m. | New approaches towards T cell receptor engineered cancer immunotherapies
    James R. Heath, Institute for Systems Biology, Seattle, Washington
  • 12:35 p.m. | Expanding the cytokine alphabet for immunotherapy
    K. Christopher Garcia, Stanford University School of Medicine, Stanford, California

Spotlight on Proffered Papers Session 1

1-1:45 p.m. | Diamond Ballroom 4-5

Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

  • 1:04 p.m. | A randomized clinical trial of donor NK cells after haploidentical HCT in high-risk AML patients*
    Inpyo Choi, Ingenium Therapeutics, Daejeon, Korea
  • 1:11 p.m. | Immune subtyping predicts response and resistance of triple negative (TN) and ER+ early-stage breast cancer to neoadjuvant immunotherapy (IO): Results from 5 IO arms of the I-SPY2 TRIAL*
    Denise Wolf, University of California, San Francisco, California
  • 1:18 p.m. | High melanoma-specific survival in patients with desmoplastic melanoma treated with single agent anti-PD-1 in SWOG S1512*
    Kari L. Kendra, The Ohio State University Wexner Medical Center, Columbus, Ohio
  • 1:25 p.m. | Countering adenosine (ADO) in rectal cancer to improve RT responses to immune checkpoint blockade: a trial to test the safety and efficacy of PD1 (AB122) and ADO dual receptor (AB928) antagonists with chemotherapy after short-course RT*
    Encouse Golden, Weill Cornell Medicine, New York, New York
  • 1:32 p.m. | Phase I clinical trial of recombinant modified vaccinia virus Ankara MQ710 in patients with solid tumors*
    Liang Deng, Memorial Sloan Kettering Cancer Center, New York, NY
  • 1:39 p.m. | Biomarker analysis from phase 2 study of agenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)*
    Samuel Cytryn, Memorial Sloan Kettering Cancer Center, New York, New York

Poster Session A / Exhibit Show / Lunch

1:45-4:45 p.m. | Platinum Ballroom A-J

spotlight sessions 1 and 2

5-6:20 p.m.

spotlight SESSION 1: Endogenous Retroviruses in the Anti-Tumor Immune Response (Dark Genome)

Diamond Ballroom 4-5

Session Chair: George Kassiotis, The Francis Crick Institute, London, England

  • 5:05 p.m. | Identification and targeting of HERV-E derived tumor-restricted antigens in kidney cancer
    Richard W. Childs, National Heart, Lung, and Blood Institute, Bethesda, Maryland
  • 5:25 p.m.
    Sebastian Amigorena, Institut Curie, Paris, France
  • 5:45 p.m. | Immunogenicity of endogenous retroelements in cancer
    George Kassiotis
  • 6:05 p.m. | Discussion / Q&A

Spotlight Session 2: T Cell Fitness, Dysfunction, and Exhaustion 

Diamond Ballroom 1-3

Session Chair: Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York

  • 5:05 p.m.
    Andrea Schietinger
  • 5:25 p.m.
    E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania
  • 5:45 p.m. | Harnessing stem cell memory T cells for next-generation CAR T cell therapy
    Luca Gattinoni, Leibniz Institute for Immunotherapy, Regensburg, Germany
  • 6:05 p.m. | Discussion / Q&A

evening off

6:20 p.m.